Advertisement
Screener

Bolt Biotherapeutics, Inc. (BOLT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.8 / 5 stars · 68/120 Roast Me

Bolt Biotherapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Bolt Biotherapeutics, Inc. (BOLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-12

  • Bolt Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Bolt Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Bolt Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Bolt Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-03-12
2024-12-310.00%
10-K · filed 2026-03-12
2023-12-310.00%
10-K · filed 2025-03-24
2022-12-310.00%
10-K · filed 2024-03-21
2021-12-310.00%
10-K · filed 2023-03-29
2020-12-310.00%
10-K · filed 2022-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
SYNLOGIC, INC. (SYBX)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Pulmatrix, Inc. (PULM)United States$0.006B
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
EXICURE, INC. (XCUR)United States$0.008B-1.54